| 臺大學術典藏 |
2020-06-22T07:36:56Z |
Tumor Endothelial Marker 1 (TEM1/Endosialin/CD248) Enhances Wound Healing by Interacting with Platelet-Derived Growth Factor Receptors
|
Hong Y.-K.;Lee Y.-C.;Cheng T.-L.;Lai C.-H.;Hsu C.-K.;Kuo C.-H.;Hsu Y.-Y.;Li J.-T.;Chang B.-I.;Ma C.-Y.;Shu-Wha Lin;Wang K.-C.;Shi G.-Y.;Wu H.-L.; Hong Y.-K.; Lee Y.-C.; Cheng T.-L.; Lai C.-H.; Hsu C.-K.; Kuo C.-H.; Hsu Y.-Y.; Li J.-T.; Chang B.-I.; Ma C.-Y.; SHU-WHA LIN; Wang K.-C.; Shi G.-Y.; Wu H.-L. |
| 國立成功大學 |
2019-10 |
Tumor Endothelial Marker 1 (TEM1/Endosialin/CD248) Enhances Wound Healing by Interacting with Platelet-Derived Growth Factor Receptors
|
Hong;Yi-Kai;Lee;Yao-Chou;Cheng;Tsung-Lin;Lai;Chao-Han;Hsu;Chao-Kai;Kuo;Cheng-Hsiang;Hsu;Yun-Yan;Li;Jui-Ting;Chang;Bi-Ing;Ma;Chih-Yuan;Lin;Shu-Wha;Wang;Kuan-Chieh;Shi;Guey-Yueh;Wu;Hua-Lin |
| 國立成功大學 |
2022-06-22 |
Tumor endothelial marker 1 is upregulated in heart after cardiac injury and participates in cardiac remodeling
|
Chen;Po-Sheng;Feng;Wen-Han;Tsai;Tzu-Hsien;Hong;Yi-Kai;Lee;An-Sheng;Chang;Kuan-Cheng;Chung;Hsing-Chun;Liu;Yen-Wen;Hsieh;Chih-Cheng;Fang;Yi-Hsian;Yang;Pei-Jung;Luo;Chawn-Yau;Liu;Ping-Yen;Cheng;Tsung-Lin;Li;Yi-Heng |
| 國立勤益科技大學 |
2009-12 |
Tumor Feature Reserved Compression Systems for Mammograms
|
林基源 |
| 國立勤益科技大學 |
2009-12 |
Tumor Feature Reserved Compression Systems for Mammograms
|
楊勝智 |
| 臺大學術典藏 |
2016 |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; CHIUN HSU; Cheng A.-L. |
| 國立臺灣大學 |
2016 |
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
|
Lu, Li-Chun; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG |
| 國立成功大學 |
2017 |
Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma
|
Chan, S.-C.;Chang, K.-P.;Fang, Y.-H.D.;Tsang, N.-M.;Ng, S.-H.;Hsu, C.-L.;Liao, C.-T.;Yen, T.-C. |
| 中國醫藥大學 |
2010-06 |
Tumor heterogeneity of Figo stage III carcinoma of the uterine cervix:In regard to Kim et al.
|
陳尚文(Shang-Wen Chen)*; 梁基安(Ji-An Liang) |
| 亞洲大學 |
2017-03 |
Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression
|
Hsieh, 林佑融；Yu-Jung Lin；Woei-Cherng；Woei-Cherng Shyu；Chi-Wei Chan；Chi-Wei Chang；Chi-Chung Wa；Chi-Chung Wang；Chung-Pu Wu；Chung-Pu Wu；Hsu-Tung Lee；Hsu-Tung Lee；Liang-Jwu Ch；Liang-Jwu Chen；謝佳宏；Chia-Hung |
| 國立臺灣大學 |
1999 |
Tumor Immunology - When a Cancer Cell Meets the Immune Cells
|
許世明; HSU, SU-MING |
| 臺大學術典藏 |
2018-09-10T07:47:37Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Sheu, B.-C. and Hsu, S.-M. and Ho, H.-N. and Lin, R.-H. and Huang, S.-C.; BOR-CHING SHEU |
| 臺大學術典藏 |
2018-09-10T07:48:02Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Sheu, B.-C. and Hsu, S.-M. and Ho, H.-N. and Lin, R.-H. and Huang, S.-C.; HONG-NERNG HO |
| 臺大學術典藏 |
2020-01-22T06:00:39Z |
Tumor immunology - When a cancer cell meets the immune cells
|
Bor-Ching Sheu;Hsu S.-M.;Ho H.-N.;Lin R.-H.;Huang S.-C.; BOR-CHING SHEU; Hsu S.-M.; Ho H.-N.; Lin R.-H.; Huang S.-C. |
| 臺大學術典藏 |
1999 |
Tumor immunology - When a cancer cell meets the immune cells
|
Huang S.-C.; Lin R.-H; HONG-NERNG HO; Hsu S.-M; Sheu B.-C; Sheu B.-C;Hsu S.-M;Hong-Nerng Ho;Lin R.-H;Huang S.-C. |
| 國立臺灣大學 |
2016 |
TUMOR INDUCED OSTEOMALACIA IN TAIWAN
|
Tsai, K. -S.; Lee, J. -C.; Shih, S. -R.; Chili, W. -Y.; Shih, S. R.; 蔡克嵩; 李仁傑; 施翔蓉 |
| 臺北醫學大學 |
1969-06 |
Tumor Inhibitions XLII Thalidasine A Novel Bisenzylisoquinoline Alkaloid Tumor Inhibitor from Thalictru dasycarpum
|
楊藏雄 |
| 臺北醫學大學 |
1969 |
Tumor Inhibitors. XLII. Thalidasine, a Novel Bisbenzylisoquinoline Alkaloid Tumor Inhibitor from Thalictrum dasycarpum
|
S. MORRIS KUPCHAN; T. H. YANG; GEORGE S. VASILIKIOTIS; MICHAEL H. BARNES; M. L. KING |
| 國家衛生研究院 |
2001-03-15 |
Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac
|
Chen, WS; Wei, SJ; Liu, JM; Hsiao, M; Lin, JK; Yang, WK |
| 國立臺灣大學 |
1988 |
Tumor Invasiveness and Prognosis in Resected Hepatocellular Carcinoma:Clinical and Pathogenetic Implications
|
許輝吉; Wu, T. T.; Wu, M. Z.; Sheu, J. C.; Lee, C. S.; Chen, D. S.; Hsieh, F. J.; Hsu, Hwei-Chi; Wu, T. T.; Wu, M. Z.; Sheu, J. C.; Lee, C. S.; Chen, D. S.; Hsieh, F. J. |
| 國立成功大學 |
2011-11 |
Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation
|
Chang, W-L |
| 臺大學術典藏 |
2021-02-02T00:45:56Z |
Tumor location on MRI determines outcomes of patients with prostate cancer after total prostate cryoablation
|
Chen C.-H.;Chen Y.-C.;Yeong-Shiau Pu; Chen C.-H.; Chen Y.-C.; YEONG-SHIAU PU |
